Unchained Labs Acquires Freeslate
Unchained Labs acquires Freeslate, marking the company’s fourth acquisition in the past 12 months.
On Feb. 18, 2016 Unchained Labs announced the acquisition of Freeslate, a provider of high-throughput solutions for biologics formulation development and small-molecule chemistry. This marks Unchained Labs fourth acquisition in the past 12 months.
According to a press announcement from Unchained Labs, Freeslate has been partnering with the biopharma industry for more than 20 years, developing configurable automation solutions. Freeslate’s FormPrep platform automates biologic formulation preparation, releasing up to 12 formulations a day with 20 minutes of preparation time.
“Freeslate has made great progress over the past five years, and this transaction makes great sense for business, our customers and employees,” said John Senaldi, president and CEO of Freeslate, in a press announcement. “Unchained Labs shares Freeslate’s commitment to customer success and I’m confident the business is in the right hands.”
In connection with this transaction, the company raised $25 million in a Series B financing. The original syndicate partners, Novo Ventures, Canaan Partners, and TPG Biotech all participated in the financing.
Source: Unchained Labs
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
